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Abstract
Background: Different types of nebulizers and interfaces are used for the treatment of adults and children with
pulmonary diseases. The purpose of this study was to determine the efficiency of a mesh nebulizer (MN) with a
proprietary adapter and a jet nebulizer ( JN) under different configurations in adult and pediatric models of spon-
taneous breathing.We hypothesize that delivery efficiency of JN andMNwill differ depending on the interface used
during aerosol therapy in simulated spontaneously breathing adult and pediatric models. While we expect that
aerosol delivery with JN will be less efficient than MN, we also hypothesize that lung deposition obtained with the
adult lung model will be more than that with the pediatric lung model in all conditions tested in this study.
Methods: A lung model using a teaching manikin connected to a sinusoidal pump via a collecting filter at the
level of the bronchi simulating a spontaneously breathing adult (Vt 500mL, RR 15 bpm, I:E ratio 1:2) or
pediatric patient (Vt 150mL, RR 25 bpm, I:E ratio 1:2). Albuterol sulfate (2.5mg/3mL) was aerosolized with
JN (Mistymax 10, Airlife) or MN (Aerogen Solo, Aerogen) with the Adapter (Aerogen Solo Adapter,
Aerogen Ltd, Galway, Ireland) using mouthpiece, aerosol mask, and valved-mask in adults and the dragon
mask, aerosol mask, and valved-mask in pediatrics (n¼3). The Adapter, specifically designed for MN, was
attached to all the interfaces used in this study with supplemental oxygen of 2 lpm, and in addition, the MP was
tested with no additional flow in the adult model. The JN was driven with 10 lpm based on the manufacturer’s
label. Drug was eluted from the filter and analyzed via spectrophotometry. Descriptive statistics, dependent
t-test and one-way analysis of variance were used for data analysis. Significant level was set at 0.05.
Results: In adults, delivery efficiency of JN with the valved mask was significantly greater than that with the
aerosol mask ( p¼0.01). Aerosol delivery of JN with the mouthpiece was not statistically significant from the
valved mask ( p¼0.123) and the aerosol mask ( p¼0.193). Drug delivery with MN with mouthpiece
(15.42– 1.4%) and valved-mask (15.15– 1.1%) was greater than the open aerosol mask (7.54– 0.39%; p¼0.0001)
in the adult lung model. With no flow mouthpiece delivery increased> 2 fold (34.9– 3.1%; p¼.0001) compared to
use of 2 lpm of flow. Using the JN with the pediatric model deposition with valved-mask (5.3– 0.8%), dragon
mask (4.7– 0.9%), and aerosol mask (4.1– 0.3%) were similar ( p> 0.05); while drug delivery with MN via
valved-mask (11.1– 0.7%) was greater than the dragon mask (6.44– 0.3%; p¼0.002) and aerosol mask
(4.6– 0.4%; p¼0.002), and the dragon mask was more efficient than the open aerosol mask ( p¼0.009)
Conclusion: The type of nebulizer and interface used for aerosol therapy affects delivery efficiency in these
simulated spontaneously breathing adult and pediatric models. Drug delivery was greatest with the valved-
mouthpiece and mask with JN and MN, while the standard aerosol mask was least efficient in these simulated
spontaneously breathing adult and pediatric lung models. Delivery efficiency of JN was less than MN in all
conditions tested in this study except in the aerosol mask. Lung deposition obtained with the adult lung model
was more than that with the pediatric lung model.
Key words: adults, aerosols, drug delivery, face mask, inhalation therapy, mouthpiece, nebulizers, pediatrics
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Introduction
Aerosol therapy is a well-establishedmethod in thetreatment of adults and children with pulmonary dis-
eases. Recent advances in aerosol medicine led to the de-
velopment of different types of nebulizers used for aerosol
therapy. Jet nebulizers ( JN) are commonly used in hospitals
because of their inexpensive and easy to use nature. However,
they require a compressor or pressurized gas source to op-
erate, and tend to be inefficient, leaving up to 1.4mL of
medication in the reservoir at end of dose.(1–4) To overcome
the limitations of JNs, several new nebulizer technologies,
such as mesh nebulizers (MN), have been developed. The
MN is electronically operated, requiring no gas to generate
aerosol, with greater efficiency associated with low residual
drug volume at end of nebulization ( < 0.1mL).(4–7)
Both JN and MN are used for the treatment of adults and
children with pulmonary diseases. However, it is well
known that airway size, breathing pattern, inspiratory flow,
and tidal volume change with age and affect drug delivery to
the lung.(2,8–11) Pulmonary deposition is higher in adults
than in pediatrics because of an increase in lung volume,
airway diameters, and inspiratory flow, as well as the de-
velopment of a consistent breathing pattern, physical and
cognitive abilities in adults. Evidence on delivery efficien-
cies of JN and MN using different interfaces in adults and
pediatrics has been limited.
There are a variety of interfaces used in aerosol therapy,
independent of the type of aerosol generator used. While
mouthpiece and face mask are used for the delivery of
aerosolized medications to adults, patients less than 3 years
of age may not be able to hold and seal the mouthpiece
between their lips reliably during aerosol therapy. There-
fore, a face mask is commonly used in the treatment of
pediatrics. However, it must be noted that use of a face mask
with pediatrics is a substantial challenge. Previous studies
emphasized the importance of a good face mask seal and
reported that the face mask was not tolerated by children
during aerosol therapy.(12–20) Also, the practice of blow-by,
directing the stream of aerosol to the face of a child has been
associated with reduced delivery compared to a tightly fit-
ting mask, with variable deposition associated with nebu-
lizer type.(21)
Although nebulizers are well-established devices in
aerosol medicine, there are different types of nebulizers and
interfaces used for aerosol therapy that raise some practical
questions among clinicians in the treatment of adults and
pediatrics with pulmonary diseases. These questions in-
clude: what is the efficiency of different nebulizers in
spontaneously breathing patients when they are used based
on the manufacturers’ recommendations? How does the
performance of a JN compare to MN using different inter-
faces in terms of drug delivery? and Is there any difference
between their use in adults and children? The purpose of this
study was to determine both the efficiency of the MN with
an adapter specifically designed to facilitate aerosol therapy
with or without low flow oxygen to spontaneously breathing
nonintubated patients and JN using different interfaces in
adult and pediatric models. We hypothesize that delivery
efficiency of JN and MN will differ depending on the in-
terface used during aerosol therapy in simulated spontane-
ously breathing adult and pediatric models. While we expect
that aerosol delivery with JN will be less efficient than MN,
we also hypothesize that lung deposition obtained with the
adult lung model will be more than that with the pediatric
lung model in all conditions tested in this study.
Methods
Lung model
As shown in Figure 1, a model using both adult and pe-
diatric teaching mannequins with anatomical face and upper
airways was connected via a collecting filter at the level of
the bronchi to a sinusoidal pump simulating spontaneously
breathing patterns for adult (Vt 500mL, RR 15 bpm, I:E
ratio 1:2) and pediatric (Vt 150mL, RR 25 bpm, I:E ratio
FIG. 1. Experimental set-up of the adult or pediatric lung
models used in this study.
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1:2). A preventing filter was used to protect the sinusoidal
pump from aerosols. A Y and elbow adapter were placed
between the mainstem bronchi of the model and the col-
lecting filter in order to prevent condensate or liquid med-
ication from reaching the filter media (Fig. 1).
Nebulizers
JN (Mistymax 10, Airlife, Carefusion, Yorba Linda CA)
and MN (Aerogen Solo, Aerogen Ltd, Galway, Ireland)
with an Adapter (Aerogen Solo Adapter, Aerogen Ltd)
were tested in both the adult and pediatric models with all
interfaces. Mistymax 10 is a single patient-use disposable
conventional jet nebulizer that continuously nebulizes the
medication, regardless of whether the patient is inhaling or
exhaling. The JN was operated at 10 lpm in accordance with
the manufacturer’s guidelines. The Aerogen Solo is an
electronically driven single patient-use aerosol generator
that utilizes a vibrating mesh, where energy applied to the
vibrational element, causes vibration of the 1000 tapered
apertures within the mesh pumping liquid through the holes.
MN was used with the Aerogen Solo Adapter (Fig. 2)
which allows administration of low flow oxygen during
aerosol administration with mask and mouthpiece. The MN
adapter has been approved for use in the European Union
and the United States. The MN and adapter were operated
with supplemental oxygen of 2 lpm with all interfaces, and
no flow with the valved mouthpiece.
Interfaces
Figure 3 represents the organizational scheme of the study.
With the adult model, the valved mouthpiece, open aerosol
mask (AirLife,Carefusion, San Diego, CA) and valved-mask
(AirLife) were used with both aerosol devices. When JN was
used with a mouthpiece in the adult lung model, a t-piece
attached to the nebulizer was configured with a mouthpiece
on patient side with a 6 inch 22mm extension tube as res-
ervoir on the other side. As pediatrics may not reliably use a
mouthpiece, the dragon mask (AirLife), open pediatric aero-
sol mask (AirLife) and valved-mask (AirLife) were tested
with the pediatric model (Fig. 4). The valved-mask was a
modifying a non-rebreathing oxygen mask with one-way
valves on ports on both sides of the mask so that gas passes
from the mask through the one-way valves on exhalation,
while limiting gas entry through the valves during inspiration.
All experiments were conducted under ideal conditions in
which each nebulizer and interface effectively sealed to the
face of the teaching mannequins to ensure the absence of
potential facemask or mouthpiece leak.
Dosage
Albuterol sulfate (2.5mg) in a total volume 3mL was
nebulized with both nebulizers in all runs. All nebulizers
were operated in accordance with the manufacturer’s rec-
ommendations and ran until nebulization ended.
Data collection
Aerosol drug delivered to an absolute filter positioned
distal to the mannequin’s mainstem bronchi was eluted with
0.1 molar N hydrochloric acid for 3min with gentle agita-
tion, and measured using a spectrophotometer (Beckman
Instruments, Fullerton, California), at a wavelength of
276 nm. The amount of drug was quantified and expressed
as a percentage of the original dose delivered. The experi-
ment was repeated three times (n = 3) for each nebulizer in
both adults and pediatrics.
Data analysis
The amount of drug depositing in the filter was expressed
as mg of drug, as well as the total fraction of the nominal dose
FIG. 2. Organizational
scheme of the study.
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placed in each nebulizer. Descriptive statistics including the
mean and standard deviations were calculated for total in-
haled mass and total inhaled mass percent. Differences in
means between inhaled mass percent for the three interfaces
used in the adult and pediatric models were compared with a
one-way analysis of variance were used for data analysis. The
Scheffe´ procedure was employed for post-hoc comparisons of
the interfaces tested in this study. The dependent t-test was
used to determine differences in inhaled drug mass percent
between JN and MN using each interface in each lung model.
Significant level was set at 0.05.
Results
Delivery efficiency of each nebulizer
using different interfaces
Table 1 shows mean – SD for inhaled mass and percent-
age of nominal dose delivered distal to the bronchi of the
adult lung model. In adults, delivery efficiency of JN with
the valved mask was significantly higher than that with the
aerosol mask ( p = 0.01). Aerosol delivery of JN with the
mouthpiece was not statistically different from the valved-
mask ( p = 0.123) and the aerosol mask ( p= 0.193) using the
adult lung model. Drug delivery with MN with mouthpiece
(15.42 – 1.4%) and valved-mask (15.15– 1.1%) was greater
than the open aerosol mask (7.54 – 0.39%; p= 0.0001). With
no flow mouthpiece delivery increased > 2 fold (34.9 –
3.1%; p = 0001) compared to use of 2 lpm of flow.
Table 2 shows mean – SD for inhaled mass and percent-
age of nominal dose delivered distal to the bronchi of the
pediatric lung model. Using the JN with the pediatric model
deposition with valved-mask (5.3 – 0.8%), dragon mask
(4.7 – 0.9%), and aerosol mask (4.1 – 0.3%) were similar
( p > 0.05); while drug delivery with MN via valved-mask
(11.1 – 0.7%) was greater than the dragon mask (6.44 –
0.3%; p = 0.002) and aerosol mask (4.6 – 0.4%; p = 0.002),
and the dragon mask was more efficient than the open
aerosol mask ( p = 0.009).
FIG. 3. Schematic illustration of the
Aerogen Solo Adapter. The adapter cham-
ber is 170mm by 46mm, with an internal
volume of 125mL. A one-way flap valve is
placed on the chamber inlet, and covers the
oxygen nipple to avoid leakage when no
oxygen is being introduced. The mouthpiece
has a one-way expiratory flap valve.
FIG. 4. Types of interfaces tested with the adult (upper) and pediatric models.
In the upper panel, adult interface from left to right include JN with MP and 6
inch 22 mmID corrugated tubing as reservoir, JN with open aerosol mask, MN
with adapter and valved mask, and MN with MP. In the lower panel, pediatric
interfaces include open aerosol mask, MN with adapter and dragon mask, and JN
with valved mask.
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Jet nebulizer versus mesh nebulizer
As shown in Table 1, delivery efficiency of JN was two-
fold less than MN when a mouthpiece or valved-mask
( p = 0.014 and p = 0.013, respectively) was used for aerosol
therapy using the adult lung model. While drug delivery
with MN attached to an open aerosol mask was significantly
less efficient than mouthpiece and valved-mask ( p = 0.0001
and p = 0.0001, respectively), aerosol deposition obtained
from mouthpiece and valved-mask showed no significant
difference using JN and MN ( p = 0.121 and p = 0.951, re-
spectively). Without supplemental O2, MN with mouthpiece
achieved > 4 fold higher deposition efficiency than JN with
MP used with the adult lung model.
JN was less efficient in drug delivery than MN using
valved-mask and trended lower with the dragon mask
( p= 0.002 and p= 0.066, respectively). Differences in aerosol
delivery between JN and MN using the open aerosol mask
was not statistically significant ( p= 0.355). While no signif-
icant difference was found between valved-mask, dragon
mask, and aerosol mask using JN, drug delivery with MN via
valved-mask was greater than the dragon mask ( p= 0.002)
and open aerosol mask ( p= 0.002). The dragon mask was
more efficient than the aerosol mask using MN ( p= 0.009).
Also, inhaled dose distal to the bronchi was marginally
greater with adults than peds with all of the masks studied
with both JN and MN ( p< 0.05).
Adult versus Infant
Aerosol deposition in the adult lung model was signifi-
cantly greater than the infant lung model using aerosol and
valved masks with JN ( p= 0.001, and p= 0.002, respectively)
and MN ( p= 0.001, and p= 0.005, respectively). Figure 5
shows comparisons of adult and infant lung model on aerosol
delivery using aerosol and valved-masks with JN and MN.
Discussion
Aerosol therapy via nebulizers is a well-established
method for treatment of patients with pulmonary diseases.
However, no consensus exists on which nebulizer to use
with which interface in adults and pediatrics. In this study,
we showed that performance of nebulizers varies with the
nebulizer type and interface used during aerosol therapy.
Delivery efficiency of JN was less than MN in all conditions
tested in this study, except in the aerosol mask in simulated
spontaneously breathing adult and pediatric lung models.
Regardless of the type of nebulizer, drug delivery via the
open aerosol mask was less than other interfaces tested with
both adult and pediatric models. In the pediatric model,
aerosol deposition obtained via the valved-mask was greater
than the dragon and open aerosol. With each type of neb-
ulizer, delivery with mouthpiece and the valved-mask were
similar.
One of the advantages of MN, generating aerosol without
requirements for oxygen or other gas flow to generate
aerosol, can be a disadvantage in patients requiring low flow
oxygen during nebulization. Unlike a JN that is typically
operated at a specific flow with oxygen or air, the MN
adapter allows low flow oxygen to be titrated based on pa-
tient needs, independent of the performance parameters of
the nebulizer, without requiring use of a blender.
The adapter was designed with a valved mouthpiece to
facilitate administration of low flow oxygen with a valved
chamber to optimize aerosol delivery. Valved holding
chambers (VHC) with valved masks and mouthpieces have
been used with aerosol devices, specifically pMDIs, for
several decades, increasing inhaled dose compared to
pMDIs alone.(22) But similar to pMDI with VHC and jet
nebulizers administered to children with masks, failure to
have a tight seal substantially reduces inhaled aero-
sol.(17,23,24) Similarly, open ports on the aerosol mask was
associated with a reduction of inhaled dose with both the
open and dragon masks compared to the valved mouthpiece
or mask.
Aerosols can be administered via either mouthpiece or
face mask. Nikander et al.(25) reported that the inhaled mass
percent of a jet nebulizer attached to a mouthpiece ranges
from 8.9% to 12.2%, as opposed to 5.0%–6.9% with a
standard nonsealed face mask. Consistent with Nikander’s
Table 1. Mean – SD for Inhaled Mass and percentage of Nominal Dose Delivered Distal
to Bronchi of Adult Lung Model
Nebulizers Jet nebulizer Mesh nebulizer at 2 lpm
Mesh nebulizer
Interfaces Mouthpiece
Valved
mask
Aerosol
mask Mouthpiece
Valved
mask
Aerosol
mask
using no O2
Mouthpiece
Inhaled mass (mg) 0.19 – 0.01 0.22– 0.01 0.17 – 0.01 0.39 – 0.03 0.38 – 0.02 0.188 – 0.01 0.87 – 0.07
Inhaled mass percent (%) 7.66 – 0.62 8.63– 0.22 6.84 – 0.49 15.42 – 1.41 15.15– 1.05 7.54 – 0.39 34.99 – 3.17
Table 2. Mean – SD for Inhaled Mass and Percentage of Nominal Dose Delivered Distal
to Bronchi of Pediatric Lung Model
Nebulizers Jet nebulizer Mesh nebulizer
Masks Valved mask Dragon mask Aerosol mask Valved mask Dragon mask Aerosol mask
Inhaled mass (mg) 0.13 – 0.02 0.116 – 0.02 0.10 – 0.01 0.277 – 0.01 0.161 – 0.01 0.11 – 0.01
Inhaled mass % 5.33 – 0.75 4.67 – 0.94 4.08 – 0.27 11.11 – 0.66 6.44 – 0.34 4.56 – 0.37
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study, we found aerosol deposition obtained via an open
face mask was lower than mouthpiece (6.84% and 7.66%,
respectively). Differences in magnitude between the
mouthpiece and face mask may be the characteristics of the
aerosol devices with the drug nebulized. Budesonide is as-
sociated with a higher particle size distribution than albu-
terol that we used, which may preferentially increase
impactive losses for aerosol passing through the nasal pas-
sages of the model.
There are a few studies that compared clinical efficacy of
the face mask with the mouthpiece. For instance, Mellon
et al.(26) found that the open face mask was as effective as
the mouthpiece in delivering budesonide inhalation sus-
pension to young children with persistent asthma. In con-
trast, Kishida et al.(27) reported that aerosol delivery via
mouthpiece leads to significant improvement in forced ex-
piratory volume in the first second (FEV1) compared to face
mask. On the other hand, Everard et al.(28) reported ap-
proximately 50% decrease in aerosol deposition in the lungs
with nasal inhalation, which is an option with mask that is
excluded with use of mouthpiece.
Although it appears to be more efficient to use a
mouthpiece with nebulizers, sick, acutely dyspneic and
uncooperative adults and children less than 3 years of age
may not be able to use a mouthpiece reliably during aerosol
therapy. In such cases, nebulizers are often used with face
masks. When a face mask is used during aerosol therapy, it
is essential to have a tight seal between face and mask in
order to avoid aerosol leakage and aerosol deposition around
the eyes.(16,24)
There are different types of face masks available on the
market for aerosol therapy. While we tested the standard
open aerosol mask with the dragon and valved-mask in the
pediatric study, only the standard face mask and valved-face
mask were compared in the adult study. Like Lin et al.,(29)
we found an increased efficiency with the valved-face mask
than the standard aerosol mask. The valved-mask contains
one-way valves on both sides of the mask that allows ex-
haled gas to exit the mask, while providing a preferential
draw of aerosol and gas from the aerosol generator/adapter
during inhalation that resulted in increased aerosol deposi-
tion in these simulated spontaneously breathing adult and
pediatric models. Restrepo et al.30 determined the amount of
aerosol delivered to a pediatric lung model via T-piece and
an aerosol mask at 0 cm, 1 cm, and 2 cm away from the
filter. The mean inhaled mass percent measured with the
aerosol mask at 0 cm was 2.88% as opposed to 4.08% in our
study. Restrepo et al.30 used a set tidal volume of 60ml and
a respiratory rate of 20 bpm whereas we used a set tidal
volume of 150ml and a respiratory rate of 25 bpm. Differ-
ences in breathing parameters may be the major source of
the differences in our findings. Similarly, Lin et al. inves-
tigated the effect of the dragon, aerosol, and fish masks on
aerosol deposition at three different distances (0 cm, 1 cm,
and 2 cm) from the face of a pediatric breathing model, with
a mean percentage of nominal dose inhaled of 2.18% and
2.65% with the aerosol mask and the dragon mask, re-
spectively.31 Lin also used the same breathing parameters as
Restrepo et al.
Although the valved mask is a nonstandard configuration,
our results suggest that the valved mask substantially in-
creased the inhaled dose with both types of aerosol generator.
However, failure to have a tight seal, as we were careful to
achieve with our models, would likely result in a substantial
reduction of inhaled drug available to the patient. Pitance and
colleagues(32) reported that both inhaled and lung dose were
greater with a nonvented nebulizer using a corrugated ex-
tension tube reservoir than use of a vented nebulizer. While
these extensions are commonly used with JN with mouth-
piece, we were surprised to find that the valved mask
FIG. 5. Comparison of adult (dark bar)
and infant (gray bar) inhaled mass percent
(Mean –SD) for open and valved aerosol
mask with jet and mesh nebulizers. Inhaled
mass was greater with adult than infant with
all conditions ( p < 0.05).
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delivered a similar level of inhaled dose, suggesting that the
volume of the mask acts as a reservoir of aerosol.
This study confirms high efficiency of aerosol delivery with
mesh nebulizers compared to jet nebulizers in simulated
spontaneously breathing patients. In the current study, drug
delivery with MN increased by up to 2-fold both in adults and
pediatricswith a flow of 2 lpm. The 2-fold increasewith valved
mask is likely clinically significant.With theMN and Adapter,
we found a 35% greater inhaled dose with the Dragon
(6.44– 0.34%) versus open aerosol mask (4.56– 0.37%).
Nonetheless, clinicians should be cautious in implying that
such an increase is clinically significant in real life situations,
particularly when there are no data about the mask seal.
We speculate that the increased inspiratory resistance
through the smaller ports with the dragon mask versus open
aerosol mask allows a greater percentage of inhaled gas to be
drawn through the adapter. However, Berlinski(33) compared
inhaled dose from JN with open aerosol masks with various
level of occlusion of the ports and reported no difference.
More than a 4-fold increase in drug delivery was observed
with the MN using MP in the adult lung model with no
oxygen flow. This is consistent with reports of higher effi-
ciency with MN than JN during mechanical ventilation,(34–36)
and with a mouthpiece.(37) Nebulizers that employ mesh
technology have a low residual volume, silent operation,
short treatment time, simplified cleaning, and the ability to
nebulize small drug volumes.(2,4,37–40)
We found that using 2 lpm with the MN attached to a
mouthpiece decreased drug delivery compared to no oxygen
flow. This is likely due to the continuous flow of gas diluting
the aerosol and displacing it from the relatively small vol-
ume spacer chamber. This is consistent with previous re-
ports that increasing bias flow leads to a dilutive effect with
a trend toward a reduction in drug delivered to adults during
mechanical ventilation in which the ventilator circuit acts as
a reservoir.(35) In contrast, with no gas flow into the adapter,
aerosol does not effectively enter the open mask. Based on
our observations and the device label, MN with open aerosol
mask requires some level of low flow gas through the
adapter to move the aerosol from the chamber into the mask.
Despite technological advances in nebulizer designs, jet
nebulizers are still extensively employed to deliver inhaled
medications to patients with pulmonary diseases. This is in
part due to the low costs associated with jet nebulizers, and
the relatively high cost of the mesh technology, especially
when administering drugs that are inexpensive such as
bronchodilators. The main problem with these nebulizers is
the continuous aerosol generation both in inhalation and ex-
halation that leads to inefficiency in aerosol drug delivery and
substantial drug loss into the environment.(2,6,41) According to
in vitro reports by Rau et al.,(42) the inhaled dose obtained
from a jet nebulizer is 14% using a simulated adult lung
model. Their results are in contrast to the findings of this
study, as we found that aerosol drug delivery with JN is
6.84%, 7.66%, and 8.63% using the aerosol mask, mouth-
piece, and valved-mask, respectively. Differences in our
findings can be explained by the models used as Rau et al.
collected the inhaled dose at the face, as opposed to our
model that collected the inhaled drug distal to the bronchi.
Since our model allows aerosol to pass through the anatomic
structures of the upper airway, the inhaled dose available to
the lung would be reduced due to impactive losses of aerosols
in the upper airway. Also, aerosols inhaled during the last
25% of inhalation are less likely to reach the filter attached to
the trachea. The findings of the pediatric study showed that
aerosol deposition with JN ranged from 4.08% to 5.33%,
which is consistent with the results of an in vivo study con-
ducted by Erzinger et al. on 18–36-month-old children.(24)
We found only marginal increases in the inhaled dose
with adults over pediatrics with the range of masks used.
The differences in airway sizes and volumes are in part
offset by the similar I:E ratios used with both models.
Limitations
This study used one set of breathing parameters for each
model; therefore, the findings of this study should not be
generalized to the wide range of breathing parameters re-
presenting different age ranges of children and sizes of
adults. Although it is well known that children usually have
highly erratic breathing patterns while awake which impacts
deposition, and this is further exacerbated by their intoler-
ance of the face mask, mimicking such changes in breathing
pattern or the failure to tolerate a closely fitting face mask
was beyond the scope of this study. Since our model pro-
vides a very consistent flow, volume, and frequency during
aerosol treatment, the findings of this study may overesti-
mate aerosol drug delivery in vivo.
The use of valved disposable face masks is not as com-
mon in aerosol delivery as in administration of oxygen or
heliox. We used these masks to better understand their im-
pact on inhaled mass with our models. While our findings of
improved inhaled dose are compelling, our evaluation does
not include the impact on CO2 rebreathing or other potential
safety concerns with their use. Further modeling and eval-
uation is recommended to determine their safety in the
clinical settings.
Also, the MN adapter is new to the market and approved
for use by the EU and FDA. Therefore the clinical experi-
ence to date is limited, with no clinical studies to date.
Clinical implications
Clinicians often question the effectiveness of nebulizers
that are used with different interfaces. In this study, we
compared the use of JN and MN with three types of inter-
faces in simulated spontaneously breathing adults and pe-
diatrics. The data indicated that MN was superior to JN in
terms of aerosol drug delivery, and aerosol deposition ob-
tained with the valved-mouth pieces and face mask was
greatest, regardless of the nebulizer tested in this study.
Efficiency of MN attached to a mouthpiece is better when
no additional flow was used with the Adapter than 2 lpm.
Further studies are needed in the clinical settings to deter-
mine the clinical efficacy of higher doses and their impact
on patients safety, outcomes and resource utilization.
Conclusion
The type of nebulizer and interface used for aerosol ther-
apy affected delivery efficiency in these simulated sponta-
neously breathing adult and pediatric lung models. Drug
delivery was greatest with the valved-mouthpiece and valved-
mask with both JN and MN, while the standard aerosol mask
was least efficient in these simulated spontaneously breathing
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adult and pediatric lung models. Delivery efficiency of JN
was less than MN in all conditions tested in this study except
with the open aerosol mask. Lung deposition obtained with
the adult lung model was more than that with the pediatric
lung model.
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